Index

3+3 design, 6, 8, 9, 12
α-trimmed mean, 504
A+B designs, 6, 8, 11, 12
A+B+C design, 12
Absolutely continuous, 519
Accelerated failure time (AFT), 160, 386
ACTG 076 trial, 519, 520
ACTG 364 study, 178
Adaptive design, 28, 34, 45, 49, 63,
519, 520
continuous (CAD), 520
delayed responses in, 44
for allocation, 518
for categorical responses, 41
for continuous responses, 42
optimal, 43
Wilcoxon-Mann-Whitney-type, 43
Adaptive estimation
in clinical trials, 508
Adaptive procedure, 505
robust, 518
in clinical trials, 518
Adaptive RPW, 40
Additive hazards regression, 160
Adherence, 84, 86, 87, 90, 92
AIDS, 83, 90, 91, 92, 94, 124, 519
Akaike information criterion (AIC), 538, 539
Algorithm
cross-validation, 103
pool adjacent violators, 9
Allocation designs
nonparametric-score-based, 42
link-function-based, 43
Allocation rule
optimal, 44
Analysis by allocation unit, 74
ANOVA, 70, 71
Anthropogenic, 123
Antiretroviral (ARV)
agent, 85, 87
drugs, 87
therapy, 84, 85, 92
Arrays. See Microarrays
Array comparative genomic
Hybridization (aCGH), 385, 400
Asymptotically measurable, 165
Asymptotic bias, 504
Asymptotics
increasing domain, 97
infill, 97
Atlas methods, 125
Atmospheric science, 136
At risk, 100, 506
Attenuation factor, 144
Autocorrelation, 111
Average sample number (ASN), 57, 60
Autoregressive model
non-Gaussian, 529
Autoregressive moving average (ARMA), 132
Avian flu, 124
AZT, 33, 34, 519

Backfitting, 125
Bandwidth, 101, 102, 103, 104, 107, 515
Baseline hazard, 160
Baseline integrated hazard, 162
Baseline survival function, 159
Bayes theorem, 9, 22, 113
Bayesian
analytic methods, 84
approach, 23, 87, 94, 113, 115, 118, 529, 530, 542
computation, 168
deconvolution model (BDM), 531, 542
design, 11, 18, 28, 45
feasible designs, 10
hierarchical framework, 117
hierarchical nonlinear model, 87
information criterion (BIC), 529, 538, 539
kriging, 112, 113
methods, 18, 23, 24, 27, 28, 84, 125, 128, 169, 396, 448, 479
model averaging, 530
modeling approach, 89
nonlinear mixed-effect model, 87, 88, 90
paradigm, 18, 22, 49
point of view, 142
prediction, 90, 92, 94
procedure, 92
semivariogram, 115
statistics, 84, 118
techniques, 506
Benefit time, 507
Beta(a,b), 23
Behrens-Fisher problem, 43
Berkson error model, 141, 142, 144
Bernoulli, 55, 56, 59
Best linear unbiased prediction (BLUP), 108, 109
Beta
distribution, 24
family, 23
function, 23
Between-cluster correlation, 68, 69
Between-cluster variance, 73
Biased coin design, 45
doubly adaptive (DBCD), 39, 40
Binary response, 143, 144, 149, 150, 152
bivariate, 142, 146
misclassified, 149
Binomial, 19, 20, 22, 23, 24, 26, 56, 59
sampling, 57, 59, 131
spending function method, 21
Biodiversity, 123
Biomarkers, 309, 465
Birth-and-death urn (BDU), 37, 38
with immigration (BDUI), 37, 38
Birth processes, 41
Block jackknife, 171
BLUP, 111, 113, 117
Boosting, 394, 444, 454
Bootstrap, 160, 163, 164, 165, 166, 167, 169
likelihood, 166
log likelihood, 169
piggyback, 160, 168, 169
weighted, 168
Breakdown point, 502, 504
asymptotic, 504, 505
finite-sample, 504
Breslow estimator, 162
Brownian bridge, 165
Brownian motion, 165
B-spline, 532, 533
cubic, 131

$\chi^2$
approximation, 125
test, 21
Cancer, 143, 151, 152, 515, 548
incidence, 506
lifetime risk of developing, 549
recurrence, 506
remission, 506
screening, 507
Carcinogenesis models, 547
biologically based, 548, 549
physiologically based pharmacokinetic (PBPK), 548, 549
Case-control
sampling, 508
studies, 74, 405, 508, 509
Cases
incident, 98
prevalent, 98
Censored data, 351, 385
right, 160, 506, 513
survival, 513, 515
Censoring
case I interval censoring, 160
current status censoring, 160
distribution, 515
induced dependent, 506
Central limit theorem, 515
Chemotherapy, 515
Childhood leukemia, 100
Cholera, 97, 123, 124, 128, 130, 131, 132, 134, 135, 136
Class
age-structured, 124
exposed, 124
geographically structured, 124
Classification, 328, 444, 450
error, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153
CLUSTER, 529, 540
Cluster
detection, 107, 119
size, 72
Clustering, 328, 365
Cluster randomization design, 73
Cluster randomized trial (CRT), 67, 68, 69, 71, 72, 73, 74, 75, 76
Coefficient of variation, 73, 152, 529
between-cluster, 73
Cohort, 8, 74, 143, 151, 152
Colored noise, 132
Comparative
phase II clinical trial, 23
studies, 17, 23
Compartment model, 124, 130
Susceptible-Infected-Removed (SIR), 124
Competing-risks data, 506
Completely randomized design, 71
Conditional independence, 147
Conjugate prior, 23
Consistent and asymptotically Normal (CAN), 134, 162, 508, 515
Contagion processes, 100
Contamination, 506, 507
infinitesimal, 504
Continual reassessment method (CRM), 6, 10, 11, 12
Continuous-time disease models, 125
models, 125, 136
processes, 124, 125
Contour plot, 116
Control theory, 125
Cook’s statistic, 513
Cortisol (hydrocortisone), 528
Covariance function, 110, 113, 114, 118
exponential family of, 114
isotropic, 114
stationary, 114
Cox model, 159, 160, 169, 171
for current status data, 161
for right-censored data, 160
partly linear, 161
Cox partial likelihood, 171
Cox proportional hazards model, 169
regression, 386
Cramer-von Mises procedure weighted, 509
Cross-contamination, 72
Cross-resistance patterns, 86
Cross-validation algorithm, 103
Cumulative cohort design, 7
Current status data, 160
Cycle detector, 529
Cytostatic drugs, 27
Cytotoxic
anticancer drugs, 27
treatments, 27
Data assimilation, 136
Death processes, 41
Decay function
exponential or bi-exponential, 530
Decision-theoretic
design, 18
paradigm, 18
Deconvolution, 528, 531, 532
Veldhuis-Johnson model, 529
Delay-adjusted procedure, 45
Demographic variability, 131
Density power divergence, 514
estimating equation, 514, 515
estimator that minimizes, 514
Depression
clinical, 46
dendogenous, 46
DerSimonian-Laird procedure, 508
Design
adaptive, 28, 34
Bayesian, 9, 11
biased coin, 34, 45
cluster randomized, 68, 73
completely randomized, 71
cumulative drop-the-loser, 43
doubly adaptive biased coin, 39, 40, 44
dose escalation, 16
drop the loser with covariate, 41
effect, 72
escalation with overdose control, 10
link-function-based allocation, 43, 63
matched-pair, 71
nonparametric-score-based allocation, 42
optimal adaptive, 43
partial sequential, 59
stratified design, 71
success-driven, 62
Wilcoxon-Mann-Whitney-type adaptive
(WAD), 43
DETECT, 529
Deviance, 508
Dichotomous response, 518, 519, 520
Differential equations, 84, 85, 87, 90
nonlinear, 84
ordinary (ODE), 131, 132
stochastic (SDE), 131, 132
Differential expression. See Microarrays
Directional derivative, 503
Discrete-time
mechanistic modeling, 125
models, 124, 125
nonlinear systems, 125
Disease
dynamics, 123, 124, 135
prevalence, 123
Distance-decay correlation function, 116
Distribution
binomial, 8, 511
bivariate normal, 146, 147
Gaussian/normal, 97, 118, 144, 148, 519
generalized gamma family of, 529
multivariate normal, 118
Poisson, 100
spatial, 97
two-cell Bernoulli, 511
Weibull, 515, 516
Distribution-free
test, 508
Divergence
density-based, 513
Dixon-Mood decision rule, 7
Dominating measure, 513, 514
Donsker class, 164, 165
Dose escalation design, 16
Dose finding, 6
Dose-limiting toxicity, 6
Dose-response, 152
model, 7
relationship, 548
Dose-response function
isotonic estimates of, 6
Dose-toxicity models, 9
Dose-toxicity relationship, 6
Dosimetry, 143, 151
Double-blind, 16
Drop-the-loser (DL), 41, 42, 48
continuous (CDL), 43, 47, 48
design with covariate (DLC), 41
for binary responses, 63
urn, 37, 38
Drug
efficacy, 84, 85, 87
exposure, 86, 87
holiday, 94
resistance, 83, 87, 94, 124
susceptibility, 84, 85
Durham-Flournoy theorem, 7, 8
Dynamic
models, 83, 84
multiprocess linear model, 529
predictions, 94
Dynamical systems
nonlinear, 124, 137
partially observed, 136
stochastic, 136
Ecological, 136
application, 126
model, 125, 128
Ecology, 124
Economics, 125
Edge effect, 105
Effective range, 111, 114, 116
Efficiency, 125, 153, 162, 502, 507, 515, 519
Elimination function
  exponential or bi-exponential, 530
Elliptical contour, 508, 509
$E_{\text{max}}$ model, 87
EM algorithm, 171
Empirical distribution, 46, 164, 502, 509, 513, 514
Endemic, 124
Environmental forcing, 136
Epidemic, 124, 136
Epidemiology, 98, 124, 141, 142, 548
  spatial, 97, 98
Episodic hormone data, 527
Episiotomy, 67, 69
Escalation designs, 8
Escalation with overdose control, 6, 10
Essential newborn care (ENC), 69
Estimating equation, 511
  generalized, 75, 507
  robust, 507, 508
  truncated, 507
Estimating equation-based method, 142
Expectation maximization (EM), 353, 375
Exponential
  covariance function, 114
  decay, 114, 529
  model, 505
Exposure-response relationship, 548
Extracorporeal membrane oxygenation (ECMO), 46, 62, 64
Failure time
  accelerated, 160, 386
  data, 160
  within-subject, 506
False discovery rate (FDR), 314, 330, 341, 473
False positive, 68
Family-wise error rate (FWER), 342, 473
First breath trial, 69
Fisher information, 134, 145, 148, 151
Fisher’s exact test, 21
Fisher’s transformation, 71
Fixed-width confidence interval, 60, 63
  for partial sequential sampling, 61
  sequential, 61
Fluoxetine trial, 46, 520
Frailty regression model
  univariate proportional hazards, 159
Frequentist
  approach, 22
  design, 18, 28
  error rates, 22
  methods, 18, 19, 20, 26, 27, 28
  paradigm, 18
Full conditional, 88
Functional model, 142
Gamma frailty model, 171
Gap-time survival function, 506, 507
Gateaux
  derivative, 503
  differentiable, 503, 504
Gaussian process
  infinite dimensional, 168
  zero-mean, 165, 507, 529
Gaussian random field, 114
Gehan-Wilcoxon test statistic, 42
Gene-environment interaction, 399, 405
Gene expression. See Microarrays
Generalized cross-validation (GCV), 538, 539
Generalized estimating equations, 75, 507
Generalized Friedman urn (GPU), 35, 36
Generalized least-square, 75
Generalized Polya’s urn (GPU), 35, 36, 38
Genetic shift, 124
Genotypic, 85
Geostatistics, 107, 108, 109, 110
Geostatistical prediction, 119
Gezmu-Flournoy group procedure, 7
Gibbs sampler, 89, 532
GML, 538
Goodman-Karsch rule, 529
Goodness of fit, 135, 509
  Bayesian $\chi^2$ statistic, 537
Gradient matching, 125
Graft-versus-host disease (GVHD), 177
Graph theoretic model, 422
Grouping error, 143
Group randomized trial, 67
Group-sequential, 59
HAART, 83, 86, 87
Hamiltonian depression scale, 46
Haplotype, 410
Hardy-Weinberg equilibrium, 405, 489
Hazardous waste, 97
Hazard function
  baseline, 159, 160
  baseline integrated, 162
Hazard rate, 548
Heatmap, 330, 372, 458
Heavy-tailed
data, 507
distribution, 507
Hellinger deviance test, 509
Hellinger distance, 509, 510, 512
Heterogeneous
  Poisson process, 102
  process, 100
Hierarchical model
  Bayesian nonlinear, 87
  for spatial prediction, 108
HIV, 33, 83, 84, 87, 89, 91, 92, 93, 124, 519
dynamic model, 84, 85
Hormonal time series data, 527
Hormone, 527, 528
decay rate of, 534
elimination of, 528
half-life of, 534
plasma concentration of, 528
pulsatile data, 528
Hormone secretion
  basal, 530
  episodic, 527, 528
  pulsatile, 530
  rhythmic, 527, 528
Host species, 124
Hyperprior, 88
Hyperparameters, 88, 89, 90, 92
Identifiability, 94, 118
Illness-death model, 506
Ill-posed problem, 528, 531
Image plot, 116
Immunity, 123, 130
Incidence, 97, 98
cancer, 549
cholera, 97
rate, 548
yellow fever, 97
Indinavir (IDV), 86, 87, 91, 92
Infection, 123, 130, 136
  human-to-human, 131
Infectious diseases, 124
Inflated degrees of freedom (IDF), 538, 539
Influence function, 502, 503, 504, 505, 510, 511
Instrumental variable, 142
Intensity
  nonparametric estimates, 100
  of a spatial Poisson process, 99, 100
Intensity function, 100, 101
  heterogeneous, 100
  kernel-based estimates, 100
  spatial, 119
Interaction
  crossover, 507
  qualitative, 507
Interclustering correlation, 68
Intergene correlations. See Microarrays
Interim analysis, 17, 19, 21, 22, 24
Intracluster correlation, 68, 70, 73, 75
Intraclass correlation (ICC), 68, 69, 70, 71, 72, 73, 74, 75
Inverse binomial
  trial, 58
  two-sided test, 57
Inverse problem, 528
Inverse sampling, 55, 59, 60, 62, 63
  binomial, 56, 57, 58, 63
  for multitreatment clinical trial, 63
  in adaptive designs, 62
  normal, 63
  two-sample randomized, 59
Isotonic
  designs, 6, 9, 11, 12
  estimates, 9, 11
Isotropy, 108, 109, 117
Iterated filtering, 129
Iterative convex minorant algorithm, 162
Iteratively reweighted least squares
  for maximum likelihood, 509
Kaplan-Meier estimate, 513, 515, 516
Kernel-based
  approaches, 119
  intensity function estimate, 100
  smoothing methods, 100, 107, 516
INDEX

Kernel
density estimate, 102, 513, 516, 517
estimate, 101, 105
function, 101
Kriging, 108, 111, 112
Bayesian, 112, 113, 117
classical, 113, 117, 118
equations, 110, 113, 117
log-Gaussian, 118
trans-Gaussian, 118
variance, 111
Kullback-Leibler divergence, 514

Likelihood ratio, 105
local, 105
Linear model
generalized, 142, 507, 508
mixed-effects, 75
Linear prediction
of Gaussian data, 108
Linear rank test, 42
Link function, 49, 144
logit, 144, 145
probit, 144, 145
Link-function-based design, 43, 63
Lipschitz class of functions, 165
Lipschitz continuous, 165
Logistic regression, 74, 75, 145, 405, 508, 509, 510, 521
prospective, 508
Log-linear model, 125
Log-rank statistic, 42
Longitudinal
data, 75, 507
response, 49
Marginal
distribution, 127
posterior distribution, 534
Markov chain, 132
aperiodic, 6
continuous-time, 131
irreducible, 6
Monte Carlo (MCMC), 84, 89, 90, 92, 108, 112, 113, 117, 118, 126, 167, 534, 536, 543
Monte Carlo with birth-death (BDMCMC), 532
Monte Carlo with reversible jump (RJMCMC), 532, 533
recurrent, 6
Markov chain designs
stationary distribution for, 6
Markov process, 41
continuous-time, 132
continuous-sample-path, 132
partially observed, 126

L1 norm, 162
L2 distance, 514
Lagrangian multiplier, 111
Latent
Gaussian variable, 146
random field, 114
variable, 149
Lead time, 507
Least absolute deviation, 166
Least squares, 166
iteratively reweighted partial, 506
ordinary, 111
weighted, 111
Lebesgue measure, 518
Length-biased sampling, 507
Leverage, 508
Lifespan study, 151
Likelihood, 23, 24, 118, 125, 126, 127, 128, 132, 166, 503
empirical, 162, 171
hierarchical, 118
local, 128
profile, 134, 162
profile log, 134, 166
ratio test, 509
score equation, 510
semiparametric, 166
sliced, 132, 133
sliced log, 133
weighted, 509, 510, 511, 512, 513, 520
Likelihood-based
adjustment, 142
analysis, 125
inference, 125, 126
methods, 142
model comparison, 136

Malaria, 124
Mallows class, 508
Mann-Whitney
scores, 60
statistics, 59, 60
Marginal
distribution, 127
posterior distribution, 534
Markov chain, 132
aperiodic, 6
continuous-time, 131
irreducible, 6
Monte Carlo (MCMC), 84, 89, 90, 92, 108, 112, 113, 117, 118, 126, 167, 534, 536, 543
Monte Carlo with birth-death (BDMCMC), 532
Monte Carlo with reversible jump (RJMCMC), 532, 533
recurrent, 6
Markov chain designs
stationary distribution for, 6
Markov process, 41
continuous-time, 132
continuous-sample-path, 132
partially observed, 126
Markov process (Continued)
  non-Gaussian, 132
  unobserved, 126
Mass spectrometry, 420, 465
Matched-pair design, 71
Maximum a posteriori (MAP), 535, 537
Maximum entropy model (MEM), 445
Maximum likelihood, 71, 111, 128, 354, 374, 406, 502, 508
  estimator (MLE), 58, 115, 125, 128, 129, 134, 145, 147, 150, 165, 170, 502, 503, 508, 510, 515, 516, 518
  inference, 159
  misclassification estimate, 508
  nonparametric estimation, 171
  restricted, 111
  semiparametric estimation, 162, 164, 170, 171
  score equation, 503, 509, 511, 515
Maximum tolerated schedule, 12
Mean integrated squared error, 103
Mean squared prediction error (MSPE), 109, 110, 111, 118
Measurement error, 87, 90, 136, 141, 145, 146, 147, 148, 151, 152, 153, 425
  in binary regression, 142
  in covariates, 142, 144, 147, 149, 150, 152
  in predictors, 143
  linear, 141, 142
  model, 141, 142
  nondifferential, 144, 146
  nonlinear, 142
Mechanistic model, 136, 550
  multi-hit, 550
  one-hit, 550
Median inhibitory concentration, 85, 86, 87
M-estimator, 502, 503, 505, 508, 509, 520
  based on Huber’s ψ function, 520
  of location, 503
  of regression, 503
  power-robust, 507
  semiparametric, 166
Metropolis-Hastings algorithm, 89, 532, 167
Meta-analysis, 74, 319, 325, 508
Michigan ECMO trial, 46
Microarrays
  array comparative genomic hybridization (aCGH), 385, 400
  biomarker identification, 309
censored survival phenotypes, 351, 385
classification, 327
  clustering, 328, 365
correlated gene expression, 309, 327, 341
differential expression (DE), 314, 328, 336, 341
  meta analysis, 319, 325
  normalization, 344
  single nucleotide polymorphism (SNP), 385, 400
timecourse experiments, 309, 315, 377
Minimum-disparity
  estimating equation, 510
  estimator, 510
Minimum-distance procedure, 505, 509
Minimum-divergence
  estimator (MDE), 515, 516
Minimum spanning trees, 106
Minimum-variance unbiased estimator, 58, 504
Minimum-volume confidence rectangle, 167
Misclassification, 141, 143, 147, 148, 149, 151, 152, 508
  maximum-likelihood estimate, 508
Missing
  proportion, 153
  response, 152
Misspecified likelihood estimation, 166
Mixed-effect model
  Bayesian nonlinear, 84
  hierarchical nonlinear, 84, 92
  nonlinear, 92
  nonlinear partial spline, 529, 530, 537
Mixed model, 507
Mixture model, 342, 365
Mixture of Dirichlet processes (MDP), 535
Model comparison
  likelihood-based, 136
Model fitting, 508
Model free designs, 12
Model selection, 125, 529
Modified play-the-winner, 36
Monte Carlo, 99, 126, 132
  error, 133
  p value, 105, 106
  randomness, 128
  sequential (SMC), 126, 127, 128, 129, 136
  simulation, 71
test, 105
variability, 134
Mortality, 131, 135, 151, 152, 513
MRPW, 34, 38
MTD, 7, 8, 9, 10, 11, 12
Multicenter clinical trials, 507
Multilevel modeling, 75
Multinomial, 76
Multiple comparison, 105
Multiple testing. See FDR, FWER
Multiprocess dynamic linear model, 529
Multistage, 20
Multistage model
Armitage-Doll, 552
linearized (LMS), 550
Multistate events data, 506
Multitreatment trials, 11
Multivariate calibration model, 506
Multivariate failure data ordered, 506
Mutations
drug-resistant, 85, 87
resistant, 85, 86
Nakamura method, 142
Negative binomial, 56, 59
Negative exponential disparity, 510
Neonatal mortality rate, 67
Neonatal resuscitation program (NRP), 69
Neyman allocation, 44
NMPSM, 538, 539, 540, 542
Noncompliance, 83, 94
Nonlinear forecasting, 125
Non-Markov transition, 506
Nonparametric
approach, 507
methods, 506
model, 502
regression, 134, 142
smoothing, 513
statistics, 501, 502, 506
Normal
approximation, 22
Normalization, 344, 471
Nugget, 111, 114
Observation process, 126
Observation space, 126
Oceanographic science, 136
Odds ratio, 26, 74, 405
family, 159
log, 75
model for right-censored data, 161
transformation, 159
Oncology, 11, 16, 26, 27
Operating characteristics, 46
Optimal adaptive design, 43
Optimal allocation rule, 44
Ordered groups, 11
Ordered probit model, 152
Ordinal, 11, 76, 152
Ordinal categorical scale, 41
Pandemic, 130
Panel data, 160
Partial sequential, 62
design, 59
sampling, 58
Pathogenesis, 83
Pathogen species, 124
P-Glivenko-Cantelli, 163, 164
Penalization, 386, 421, 459, 528
Penalized likelihood estimation, 166, 168
Penalized maximization, 162
Pearson residual, 510, 511
Permutation, 319, 320, 357
test, 74
Persistent pulmonary hypertension of the newborn (PPHN), 62
Perspective plot, 116
Perturbation, 141, 504, 505
random, 132
P-Glivenko-Cantelli, 163, 164
Pharmacokinetics, 83, 84, 87, 90, 92
Phase I trials, 16, 23, 45, 91
Phase II, 15, 16, 17, 18, 19, 21, 23, 24, 25, 26, 27, 28, 91
Phase III, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 33, 49
PhenoSense HIV, 92
Phenotype assays, 87
Phenotypic
marker, 85, 90, 92
tests, 85
Plasma concentration-time curve
area under, 87
Play-the-winner (PW), 34, 38, 46, 63
randomized (RPW), 34, 35, 37, 38, 39, 40, 41, 46, 48, 49, 62, 63
Poisson
process (homogeneous spatial), 99
process (heterogeneous spatial), 100
random variable, 99
regression models (spatial), 99
Poisson process, 163
heterogeneous, 102
heterogeneous spatial, 100
homogeneous spatial, 99
first-order (mean) properties of, 100
second-order properties of, 100
Polya urn (Polya-Eggenberger urn), 35
generalized (GPU), 35, 36, 38
randomized (RPU), 36, 37, 38
Population dynamics, 124, 131
Population models, 123, 124, 125, 128
continuous-state, 131
deterministic, 124
discrete-state, 131
mechanistic, 124
phenomenological, 124
stochastic, 124
Posterior, 49
distribution, 23, 24, 89, 112, 113, 114, 118
kernel estimate of, 114
mean, 115, 116
median, 115
mode, 115
predictive distribution, 89, 113, 116, 117
predictive expectation, 113
predictive mean, 116, 117
probability, 24, 25
Postherpetic neuralgia, 47
Postpartum hemorrhage, 67
Power, 18, 22, 43, 44, 55, 60, 106, 507
Power law, 422
Prediction credible interval, 92, 93
Predictive density/distribution, 49, 90
conditional, 89
local variance of, 116
mean of, 116
Predictive variance, 116
Pregabalin trial, 47
Prevalence, 97, 98, 123
Princeton robustness study, 502
Principal-component regression
robust, 506
Principal components analysis (PCA), 369, 393, 396, 476
Prior distribution, 22, 23, 24, 25, 90, 113, 117, 118, 125
conjugate, 114
discrete, 114
flat, 114
gamma, 88
inverse gamma, 533
inverse Wishart, 114
Jeffreys’, 114
lognormal, 534
negative binomial, 533
normal, 88
reference, 114
vague, 114
Wishart, 88
Prior
information, 94
parameters, 114
probability, 118
Probability of disease, 548
Profile likelihood, 134, 167, 168
semiparametric, 167
Profile log likelihood, 134, 170
Profile sampler, 166, 168
Proof-of-concept studies, 15, 17
Proportional odds model, 159, 169
for right-censored data, 160
Prospective, 405, 508
Protease inhibitor (PI), 83, 85, 86, 87, 90
PULSAR, 529
Pulse, 527, 528, 529
gamma-shaped, 529
Pulsefit, 529
Pulsatile hormone data, 528
criterion-based methods for, 528
general biophysical model for, 530
model-based methods for, 528
Pure birth process
continuous-time, 37
Quadratic approximation, 134, 135
Quantal response data, 549
INDEX

R, 101
ASSIST library, 539
geoR library, 111, 114
KernSmooth library, 101
PULSE package, 539
splancs library, 101
Radiation, 143, 151, 515
Random effect model, 75, 136, 508
logit, 152
one-way, 71
probit, 152
proportional hazards regression, 169
Random forests, 395, 444, 451
Randomized play-the-winner (RPW), 34, 35, 37, 38, 39, 40, 41, 46, 48, 49, 62, 63, 519
adaptive (ARPW), 40
Randomized Polya Urn (RPU), 36, 37, 38
Random-walk rule, 11
Rank-based procedures, 507
Rapid-eye-movement latency (REML), 46
Receiver operating characteristic (ROC) curve, 343, 397, 445, 448, 449
Recording error, 143
Recurrent events, 506
Regression
additive hazards, 160
binary, 144, 152
bivariate binary, 146
bivariate isotonic, 11
logistic, 74, 75, 145, 405, 508, 509, 511
nonparametric, 134, 142
prospective logistic, 508
Regularization. See Penalization
Regular parameter, 160, 165
Remote sensing, 119
Renewal theory, 57, 58
Repeated-events data, 506
Resampling, 127
systematic, 127
Reservoir, 130, 131
Residual
standardized prediction, 135
Residual adjustment function (RAF), 510, 511, 512
Hellinger, 513
negative exponential, 513
Response-adaptive designs, 34, 49
trial, 47
Retrospective, 123, 405, 508
Reverse transcriptase inhibitor (RTI), 83, 85, 86, 87
Rheumatoid arthritis, 46
RIC, 538, 539
Risk, 98
attributable, 105
background, 106
of disease, 100
local relative, 105
log relative, 102, 103, 104, 105, 106, 107
relative, 102, 105
Ritonavir (RTV), 86, 87, 91, 92
RNA, 91, 92, 93
Robust/robustness, 103, 119, 501, 502, 503, 505, 506, 507, 508, 509, 511, 512, 515, 519, 520, 521
adaptive methods in clinical trials, 518
B-, 502
estimating equations, 507, 508
infinitesimal approach to, 503
minimax approach to, 502, 503
qualitative, 502
quantitative, 502
Rosenberg-Stallard-Ivanova-Harper-Ricks (RSIHR) rule, 44, 48
RPW(\alpha, \beta), 35, 44
Sampling
inverse, 55, 59, 60, 62
inverse binomial, 56, 57, 58, 63
inverse normal, 63
partial sequential, 58
“Sandwich” variance estimator, 75
SaTScan, 105, 106
Scan statistic, 105, 107
circular, 107
spatial, 105
Screening study, 22
Seasonal transmissibility, 135
Seasonality, 136
Semi-competing risks problem, 177
Semiparametric, 159, 352, 405, 474, 507
maximum likelihood estimation (SPMLE), 162, 164
Semivariogram, 110, 111, 112, 113, 114, 115, 117, 118
empirical, 111, 112, 114
exponential model for, 111, 113
isotropic, 110
parametric families, 111
stationary, 110
theoretical, 111, 112
Sensitivity analysis, 75
Sequence data, 326, 443
Sequential, 17, 20, 21, 22, 24, 57, 58, 62, 63
estimation-adjusted urn (SEU), 38
maximum likelihood estimation, 39, 40
ML design, 63
Monte Carlo (SMC), 126, 127, 128, 129, 136
S-estimator, 508
Severe acute respiratory syndromes (SARS), 124
Signature, 327, 368, 472
Sill, 110, 111, 114
posterior distribution of, 115
Simon design, 21
Simulated annealing, 132
Simulation extrapolation (SIMEX), 142
Single-arm, 20, 22, 23, 24, 25, 27
Single nucleotide polymorphism (SNP), 385, 400, 414, 490
Single-stage
design, 21
procedure, 22
Single-treatment pilot study, 17
Sliced likelihood, 132, 133, 134
plot, 132, 133
Smoothing, 347, 471, 490
kernel-based, 100
parameter, 101
Sobolev space, 162
Spanning trees
minimum, 106
Spatial
correlation, 98, 99, 108, 110
covariance, 108, 110, 114
data, 98
density function, 100, 102
epidemiology, 97, 98, 107, 108, 118, 119
information, 98
intensity function, 119
pattern, 98, 99, 100, 116
point pattern, 98, 100
point process, 99, 107, 119
Poisson process, 99, 100, 119
Poisson regression models, 99, 119
prediction, 98, 107, 108, 109, 113, 117, 119
random field, 113
scan statistic, 105, 106
statistics, 97, 117
trend, 98
Spatiotemporal
data, 136
model, 136
problem, 136
variability, 136
Spending function method, 21
Standardized prediction residuals, 135
State process, 126, 127
State space, 126
State space model (SSM), 125, 126, 132, 134, 135, 136
Gaussian, 125
linear, 125
nonlinear, 125, 126
Stationarity, 108, 117
Stationary distribution, 128
for Markov chain designs, 6
of dose assignments, 6
Stationary point equation, 162
Statistical functional, 502
Stochastically smaller, 60
Stochastic differential equation model, 529
Stochasticity
demographic, 124, 131
environmental, 124, 131
Stochastic optimization
Robbins-Monro type, 128
Stopping rule/criterion, 24, 57, 58, 59, 519
Stratified design, 71
Strongly consistent, 60
Structural model, 132, 142
Success-driven design, 62
 Sufficiency, 502
 Supervised learning. See Classification
Support vector machine (SVM), 454
Surrogate, 141, 143, 144, 146, 148, 149, 150, 152
Survival analysis, 159, 506
Survival curve, 507, 513
Survival data
  case-cohort estimators of, 507
censored, 508
doubly censored, 169
Survival function, 161
  baseline, 159
Survival model
  semiparametric, 159
Susceptible, 124, 130
Susceptible-Infected-Removed (SIR), 124

Taylor series, 125
T cells, 85
Thall-Simon design, 24
Thomas-Hultquist procedure, 71
Thymus, 85
Timecourse experiment. See Microarrays
  Time-series, 135, 136
    data, 124
    hormonal data, 527
    models, 125
Time-to-event, 10, 76
Time-to-event models
  general product hazards models, 552
  log-linear models, 552
  multi-event models, 552
  relative and additive risk models, 552
Time-varying, 84, 85, 87
  coefficient model, 160
TITE-CRM, 10
Tolerance distribution model, 549
  log-probit, 550
  logit, 550
  normal (probit), 549
Tobler’s first law of geography, 107
Toxicity, 26
  rate, 7, 8, 9
  monotonicity, 12
Toxicology, 512, 548
Transcription factor binding sites, 377, 443
Transformation invariance, 125
Transformation model, 159
Transmissibility, 135
  seasonal, 135
Transmission, 123
  human-to-human, 130
  vertical, 519
Treatment effect
  mapping, 41, 42
  models, 84, 85
Trimmed mean, 505, 507
Two-stage
  design, 21
  procedure, 22, 508
Type I error, 18, 19, 20, 21, 22, 26, 27, 28
Type II error, 18, 19, 21, 26
ULTRA, 529
Unbiasedness, 118
Uniformly most powerful (UMP), 56
  unbiased, 57
Unimodal prior, 23
Unit of analysis error, 68
United States Environmental Protection Agency (USEPA), 108
Unsupervised learning. See Clustering
Up-and-down designs
  Markovian, 6
  Markovian-motivated nonparametric, 6
  Markovian group, 8
Upper level set approach, 106
Utility function, 25
Variance components, 75, 131
Variance-covariance matrix, 110, 114
  positive definite, 110
Variance inflation factor, 72, 74
Variation
  between-subject, 88
  within-subject, 88
Variogram, 117
Variography, 111
Vibrio cholerae, 130, 135
Viral
  dynamics, 84, 86, 87, 89
  load, 83, 84, 87, 89, 90, 91, 92, 94
  rebound, 90, 92, 94
Virion, 85
Virological marker, 83
<table>
<thead>
<tr>
<th>Term</th>
<th>Page(s)</th>
<th>Term</th>
<th>Page(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weibull</td>
<td>515</td>
<td>Within-cluster correlation</td>
<td>68, 69</td>
</tr>
<tr>
<td>MLE fit</td>
<td>516, 517</td>
<td>Within-cluster variance</td>
<td>73</td>
</tr>
<tr>
<td>model</td>
<td>550</td>
<td>Yeast two-hybrid (Y2H)</td>
<td>325, 419</td>
</tr>
<tr>
<td>robust (MDE) fit</td>
<td>516, 517</td>
<td>Yellow fever</td>
<td>97</td>
</tr>
<tr>
<td>two-component mixture</td>
<td>516, 517</td>
<td></td>
<td></td>
</tr>
<tr>
<td>White noise</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gaussian</td>
<td>132</td>
<td>Zidovudine</td>
<td>33, 519</td>
</tr>
<tr>
<td>Wilcoxon-Mann-Whitney</td>
<td>42, 43</td>
<td>Zoonotic</td>
<td>124</td>
</tr>
<tr>
<td>Winsorized mean</td>
<td>505</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within-cluster variance</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yeast two-hybrid (Y2H)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Yellow fever</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zidovudine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Zoonotic</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**INDEX**

582